Skurikhin Evgenii, Pershina Olga, Zhukova Mariia, Widera Darius, Ermakova Natalia, Pan Edgar, Pakhomova Angelina, Morozov Sergey, Kubatiev Aslan, Dygai Alexander
Laboratory of Regenerative Pharmacology, Goldberg ED Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Centre of the Russian Academy of Sciences, Tomsk, Russia.
Stem Cell Biology and Regenerative Medicine Group, School of Pharmacy, University of Reading, Reading, United Kingdom.
Front Cell Dev Biol. 2021 Dec 3;9:778020. doi: 10.3389/fcell.2021.778020. eCollection 2021.
Despite the increasing urgency of the problem of treating small cell lung cancer (SCLC), information on the causes of its development is fragmentary. There is no complete understanding of the features of antitumor immunity and the role of the microenvironment in the development of SCLC resistance. This impedes the development of new methods for the diagnosis and treatment of SCLC. Lung cancer and chronic obstructive pulmonary disease (COPD) have common pathogenetic factors. COPD is a risk factor for lung cancer including SCLC. Therefore, the search for effective approaches to prevention, diagnosis, and treatment of SCLC in patients with COPD is an urgent task. This review provides information on the etiology and pathogenesis of SCLC, analyses the effectiveness of current treatment options, and critically evaluates the potential of chimeric antigen receptor T cells therapy (CART therapy) in SCLC. Moreover, we discuss potential links between lung cancer and COPD and the role of endothelium in the development of COPD. Finally, we propose a new approach for increasing the efficacy of CART therapy in SCLC.
尽管治疗小细胞肺癌（SCLC）问题的紧迫性日益增加，但其发展原因的信息却支离破碎。目前对于抗肿瘤免疫的特征以及微环境在SCLC耐药发展中的作用尚未完全了解。这阻碍了SCLC诊断和治疗新方法的开发。肺癌和慢性阻塞性肺疾病（COPD）具有共同的致病因素。COPD是包括SCLC在内的肺癌的一个危险因素。因此，寻找针对COPD患者预防、诊断和治疗SCLC的有效方法是一项紧迫任务。本综述提供了有关SCLC病因和发病机制的信息，分析了当前治疗方案的有效性，并批判性地评估了嵌合抗原受体T细胞疗法（CART疗法）在SCLC中的潜力。此外，我们讨论了肺癌与COPD之间的潜在联系以及内皮细胞在COPD发展中的作用。最后，我们提出了一种提高CART疗法在SCLC中疗效的新方法。
